Biotech | April 25, 2022
CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Support for biologics manufacturability and Industry 4.0 initiatives
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Subscribe To Our Newsletter & Stay Updated
